Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2017
Pharmacy Choice - News - Pharmaceutical Development - April 23, 2017

Pharmacy News

 Pharmaceutical Development
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

4/23/17 - 5 Top NASDAQ Biotech Stocks: Neurocrine Biosciences Gained 32.68 Percent
Late last week Fiercebiotech reported on XBiotech likely getting rejected by the European Medicines Agency. Last week the company revealed its lead candidate is closer to obtaining FDA approval while saying it is tentatively targeting Q4 to launch and NDA. CytRx Corporation gained 40.82 percent last week to finish at $0.61 per share.
4/23/17 - British Journal of Dermatology Issues 16 Research Articles in April 2017 Edition
Coauthors: C.E.M. Griffiths, D. Thaci, S. Gerdes, P. Arenberger, G. Pulka, K. Kingo, J. Weglowska, on behalf of the EGALITY study group, N. Hattebuhr, J. Poetzl, H. Woehling, G. Wuerth and M. Afonso. Emery, G.A. Abel, Z. Teoh, S. Hall, R.D. Neal, P. Murchie and F.M. Walter. Coauthors: M.A. Weinstock, J.P. Lott, Q. Wang, L.J. Titus, T. Onega, H.D. N
4/23/17 - CHMP Recommends Approval Of Sandoz Biosimilar Rituximab And Etanercept In Europe
BASEL- Sandoz, a Novartis division, announced that the Committee for Medicinal Products for Human Use has recommended approval of both Sandoz' biosimilar rituximab and biosimilar etanercept in Europe for the same indications as their respective reference medicines. Subject to EC approval, Sandoz market leadership position extended as the only compa
4/23/17 - Data on Clinical Trials and Studies Described by Researchers at Fred Hutchinson Cancer Research Center [Midyear Commentary on Trends in Drug Delivery...
Data on Clinical Trials and Studies Described by Researchers at Fred Hutchinson Cancer Research Center. According to news reporting originating in Seattle, Washington, by NewsRx editors, the research stated, "Before the 2009 Biologics Price Competition and Innovation Act that enabled the U.S. Federal Drug Administration to create the 351 Biologic L
4/23/17 - FDA approves drugs more quickly than peer agency in Europe
By a News Reporter-Staff News Editor at Medical Letter on the CDC& FDA New Haven, Conn. The U.S. Food and Drug Administration reviews and approves new medicines in a shorter timeframe than its peer agency in Europe, the European Medicines Agency, says a Yale researcher. This finding, which comes at a time when the FDA is under renewed pressure
4/23/17 - FDA clears heart disease trial at Boston Children's Hospital using mesoblast's cell therapy
By a News Reporter-Staff News Editor at Heart Disease Weekly BOSTON, NEW YORK, and MELBOURNE, Australia, Boston Children's Hospital, the pediatric teaching hospital of Harvard University, and Mesoblast Limited announced that the United States Food and Drug Administration has cleared the commencement of a 24- patient trial combining Mesoblast's.
4/23/17 - Recent Findings in Heart Failure Described by Researchers from Okayama University Hospital [Intracoronary Cardiac Progenitor Cells in Single...
Recent Findings in Heart Failure Described by Researchers from Okayama University Hospital[ Intracoronary Cardiac Progenitor Cells in Single Ventricle Physiology The PERSEUS (Cardiac Progenitor Cell Infusion to Treat Univentricular Heart...]. By a News Reporter-Staff News Editor at Heart Disease Weekly Current study results on Heart Disorders and
4/23/17 - Researchers at Cardiac Surgery Division Report New Data on Post-Trial Research (Single versus double antiplatelet therapy in patients undergoing...
Researchers at Cardiac Surgery Division Report New Data on Post-Trial Research. By a News Reporter-Staff News Editor at Heart Disease Weekly Current study results on Clinical Trials and Studies- Post-Trial Research have been published. According to news reporting originating from Rome, Italy, by NewsRx correspondents, research stated, "Coronary..
4/23/17 - TAGRISSO osimertinib Receives US FDA Full Approval
By a News Reporter-Staff News Editor at Heart Disease Weekly AstraZeneca announced that the US Food and Drug Administration has granted full approval for TAGRISSO 80 mg once-daily tablets, for the treatment of patients with metastatic epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer, as detected by an FDA- ap
4/22/17 - Achillion Announces Additional Phase 2 Results Including 100% SVR24 for Genotype 1 HCV After 6-Weeks of Once Daily JNJ-4178
Achillion Pharmaceuticals, Inc. announced today the presentation of updated results from the ongoing phase 2 604 Study being conducted by Alios BioPharma Inc., part of the Janssen Pharmaceutical Companies. These results were presented as an oral presentation during the European Association for the Study of the Liver 2017 International Liver
4/22/17 - AP Top Health News at 2:46 a.m. EDT
Future of revamped health care bill remains dubious in House FDA approves 2nd near-copy of Remicade for immune disorders Indian public health group loses permit for foreign funds Lawmakers revisiting requiring those on Medicaid to work FDA further restricts pain medication use in kids Italy upholds vaccine requirements for preschoolers Germ in raw.
4/22/17 - AP Top Health News at 6:04 a.m. EDT
Future of revamped health care bill remains dubious in House FDA approves 2nd near-copy of Remicade for immune disorders Indian public health group loses permit for foreign funds Lawmakers revisiting requiring those on Medicaid to work FDA further restricts pain medication use in kids Italy upholds vaccine requirements for preschoolers Germ in raw.
4/22/17 - Arbutus Announces ARB-1467 Data Presentation at EASL
Arbutus Biopharma Corporation, an industry-leading Hepatitis B Virus therapeutic solutions company, presented results of the first three cohorts of a Phase II study of its RNAi agent, ARB-1467, at the European Association for the Study of the Liver in Amsterdam, The Netherlands.. We are very pleased to present updated Phase II results for ARB-
4/22/17 - Astellas to Acquire Ogeda SA
By a News Reporter-Staff News Editor at Obesity, Fitness& Wellness Week- Astellas Pharma Inc. and Ogeda SA announced that Astellas and Ogeda shareholders have entered into a definitive agreement under which Astellas has agreed to acquire Ogeda a privately owned drug discovery company. Under the agreement, Astellas has agreed to pay up to a total
4/22/17 - Auris Medical Holding AG and Otonomy Seek FDA Approval for Drugs to Treat Ear Disorders
Auris Medical Holding AG and Otonomy Inc are set to release late-stage data from drug trials on treatments that could be used for tinnitus and Mnire's disease, according to an article in Reuters.
4/22/17 - BeiGene Announces Initiation of First Pivotal Study in China of PD-1 Antibody BGB-A317 [Syrian Arab News Agency]
-BeiGene, Ltd., a clinical-stage biopharmaceutical company developing molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the first patient was dosed in a pivotal clinical trial of BGB-A317, an investigational anti-PD-1 antibody, in Chinese patients with relapsed or refractory classical Hodgkin lymphoma.
4/22/17 - DGAP-Adhoc: MOLOGEN AG: Results of the exploratory phase II study in extensive-disease small-cell lung cancer (SCLC) (english)
MOLOGEN AG: Results of the exploratory phase II study in extensive-disease small-cell lung cancer ^ DGAP-Ad-hoc: MOLOGEN AG/ Key word: Study results MOLOGEN AG: Results of the exploratory phase II study in extensive-disease small-cell lung cancer 22- Apr-2017/ 21:49 CET/ CEST Disclosure of an inside information acc. to Article 17 MAR, transmitted b
4/22/17 - FDA approves gammaCore for treatment of pain linked to cluster headache [T-break Tech (Middle East)]
This is the first FDA product release for electroCore in the U.S.. "Cluster headache is a rare, debilitating and difficult to treat disorder with few effective acute therapies, said Stephen Silberstein, MD, Director, Headache Center, Jefferson University, Philadelphia, PA." The FDA release of gammaCore is an important advance in the treatment of t
4/22/17 - Mateon Announces Initiation of Investigator-Sponsored Phase 1 Study of CA4P in Combination with Everolimus in Neuroendocrine Tumors [T-break Tech (Middle East)]
Mateon Therapeutics, Inc., a biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced that the Markey Cancer Center at the University of Kentucky has enrolled the first patient into a new phase 1 study of CA4P in combination with everolimus for the treatment of neuroendocrine.
4/22/17 - Merck Announces New Phase 2 Data on Investigational Triple Combination Therapy MK-3682B for Chronic Hepatitis C
Merck, known as MSD outside of the United States and Canada, today announced the first sustained virologic response 1 results 12 weeks after completion of therapy from C-SURGE, an ongoing, open label Phase 2 clinical trial evaluating MK-3682B, the company s investigational triple-combination therapy in treatment-experienced patients with hepatit
4/22/17 - NewLink Genetics Announces Presentation of Two Abstracts at ASCO [Syrian Arab News Agency]
-NewLink Genetics Corporation, a biopharmaceutical company focused on bringing novel immuno-oncology therapies to patients with cancer, today reported that two abstracts will be presented at the 2017 American Society of Clinical Oncology Annual Meeting in Chicago. NewLink Genetics is a biopharmaceutical company at the forefront of discovering,...
4/22/17 - Onconova Therapeutics Announces Pricing of Public Offering of Common Stock [Gulf Daily News (Bahrain)]
-Onconova Therapeutics, Inc., a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes today announced that it has priced an underwritten public offering of 2,476,190 shares of its common stock, at a price to the public of $2.10
4/22/17 - Pharma Healthcare Newsletter April 17 to April 21, 2017 [India Infoline News Service]
This week, Pharma major Glenmark Pharma has received tentative approval from the United States Food& Drug Administration to sell Pradaxa Drug used to prevent blood clots. Top News. Unichem Laboratories Limited on Monday announced that for Piroxicam Capsules USP 10 mg& 20 mg, it has received ANDA approval from the United States Food and Drug A
4/22/17 - Promising Pediatric Data for Albireo's A4250 to be Presented at The International Liver Congress? 2017
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced that the embargo on its late-breaker abstract discussing preliminary data from a Phase 2 clinical trial of its lead product candidate A4250 in children with cholestatic liver disease has been lifted and the data will be..
4/22/17 - Rasna Therapeutics Names Dr. Kunwar Shailubhai As New CEO Rasna Therapeutics,Inc. [Palestine News Network]
Kunwar Shailubhai, CEO of Rasna Therapeutics, Inc.. Dr. Shailubhai, who was formally appointed on April 14th, was a co-founder and served as the Chief Scientific Officer and prior Senior Vice President, Drug Discovery, of Synergy Pharmaceuticals Inc. from 2004, where he led the development of Trulance from inception to FDA approval, having co-inven
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415